Maximum quantity allowed is 999
Please select the quantity
CAS RN: 850140-72-6 | Product Number: A2870
Afatinib
×
![]()
×
Purity: >97.0%(HPLC)(N)
Synonyms:
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 50MG |
NT$4,240
|
3 | 39 | It can be shipped in about 3-4 weeks after ordering | |
| 250MG |
NT$13,480
|
11 | 12 | It can be shipped in about 3-4 weeks after ordering |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
| Product Number | A2870 |
| Purity / Analysis Method | >97.0%(HPLC)(N) |
| Molecular Formula / Molecular Weight | C__2__4H__2__5ClFN__5O__3 = 485.94 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 250MG-Glass Bottle with Plastic Insert (View image), 50MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 850140-72-6 |
| Reaxys Registry Number | 11746023 |
| PubChem Substance ID | 468590121 |
| MDL Number | MFCD12407405 |
Specifications
| Appearance | White to Orange to Green powder to crystal |
| Purity(HPLC) | min. 97.0 area% |
| Purity(with Total Nitrogen) | min. 97.0 % |
| Water | max. 3.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 102 °C |
GHS
Related Laws:
Transport Information:
| H.S.code* | 2934.99-000 |
Application
Afatinib: An Irreversible Inhibitor of the ErbB Family of Tyrosine Kinases
Afatinib (BIBW-2992) is an irreversible inhibitor of the ErbB family of tyrosine kinases. The ErbB receptor tyrosine kinase family consists of four cell surface receptors: ErbB1/EGFR/HER1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4. Deregulation of the ErbB receptor network is well recognized as an oncogenic driver in epithelial cancers. Afatinib downregulates ErbB signaling by covalently binding through a Michael addition reaction to the kinase domains of ErbB1/EGFR/HER1, ErbB2/HER2 and ErbB4/HER4, irreversibly inhibiting tyrosine kinase autophosphorylation. Afatinib was approved by FDA for the treatment of EGFR mutated non-small cell lung cancer in 2013. (The product is for research purpose only.)
References
- 1) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- 2) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker
- 3) Afatinib: First Global Approval (a review)
- 4) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.